

Diese Meldung kann unter <http://www.presseportal.de/pm/56778/1433276/fda-approves-multaq-r-for-patients-with-atrial-fibrillation-or-atrial-flutter> abgerufen werden.



FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter

02.07.2009 - 10:11 Uhr, sanofi-aventis Group

Paris (ots/PRNewswire) - - Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter

- U.S Commercial Launch Planned for the Summer of 2009

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq(R) is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.

Multaq(R) is an anti-arrhythmic indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted. Associated cardiovascular risk factors include age over 70 years, hypertension, diabetes, prior cerebrovascular accident, left atrial diameter greater than or equal to 50 mm or left ventricular ejection fraction [LVEF]

Originaltext:

sanofi-aventis Group

Pressemappe:

<http://www.presseportal.de/pm/56778/sanofi-aventis-group>

Pressemappe als RSS:

http://presseportal.de/rss/pm_56778.rss2